Scrip’s Mumbai-based senior editor Vibha Ravi speaks with Dr B N Manohar, CEO of Indian cell and gene therapy firm Stempeutics Research. The company counts Cipla as an investor and has partnered with both Cipla and Alkem Labs for the marketing of cell therapy Stempeucel. This became the first patented cell therapy platform to be approved for commercial use in India, for knee osteoarthritis and critical limb ischemia. Manohar talks about these and other topics including plans and strategy.